Bioanalytical Systems (BASI) Getting Somewhat Positive Press Coverage, Study Shows

News headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bioanalytical Systems earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news stories about the company an impact score of 47.1852923811218 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Bioanalytical Systems (NASDAQ BASI) opened at $2.05 on Wednesday. The company has a quick ratio of 0.51, a current ratio of 0.64 and a debt-to-equity ratio of 0.60. Bioanalytical Systems has a fifty-two week low of $0.63 and a fifty-two week high of $2.42.

Bioanalytical Systems (NASDAQ:BASI) last released its earnings results on Monday, August 14th. The company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $5.84 million for the quarter. Bioanalytical Systems had a negative net margin of 5.88% and a negative return on equity of 20.72%.

COPYRIGHT VIOLATION WARNING: This report was originally published by Stock Observer and is the property of of Stock Observer. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.thestockobserver.com/2017/11/15/bioanalytical-systems-basi-getting-somewhat-positive-press-coverage-study-shows.html.

About Bioanalytical Systems

Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.

Insider Buying and Selling by Quarter for Bioanalytical Systems (NASDAQ:BASI)

Receive News & Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply